ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年12月24日 17時00分
Source:
Eisai
エーザイ、人事異動ならびに組織改編（2021年1月1日付）を発表
東京, 2020年12月24日 - (JCN Newswire) - エーザイは本日、人事異動ならびに組織改編（2021年1月1日付）を発表しました。
2021年1月1日付 人事異動
■ エーザイ・ジャパン
新任務／旧任務／氏名
ADF推進本部 東日本hhcエリアコーディネーターリード／ADF推進本部 hhcエリアコーディネーターリード／臼杵 尚之助
ADF推進本部 中日本hhcエリアコーディネーターリード／ADF推進本部 hhcエリアコーディネーター アソシエートディレクター／峯岸 誠
AFD推進本部 西日本hhcエリアコーディネーターリード／ADF推進本部 hhcエリアコーディネーター アソシエートディレクター／田浦 隆玄
2021年1月1日付 主な組織改編
■ エーザイ・ジャパン
1. ADF（Alzheimer's Disease Franchise）推進本部 hhcエリアコーディネーターの再編
地域診療体制構築の加速に向けて、ADF推進本部におけるhhcエリアコーディネーターを東日本、中日本、西日本の3エリア体制に再編する。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202086.html
概要：エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Power Lands Significant Gas Turbine Order for Qatar's Facility E IWPP Project
Jan 14, 2026 18:58 JST
Mitsubishi Motors Launches Updated Outlander PHEV in Canada
Jan 14, 2026 17:38 JST
Hitachi High-Tech launches FOUNDRY-MASTER Smart 2, enhancing performance and value of stationary optical emission spectrometers
Jan 14, 2026 14:10 JST
Fujitsu launches demonstration experiment into green steel value flow utilizing blockchain technology to accelerate decarbonization in the steel Industry
Jan 14, 2026 10:52 JST
Toyota Systems, Fujitsu utilize quantum-inspired technology and AI to streamline on-board computer design and contribute to sustainable development
Jan 14, 2026 10:36 JST
Mitsubishi Motors Starts Production of Rogue Plug-in Hybrid and Navara OEM Models for Nissan
Jan 13, 2026 16:02 JST
Additional Investment in Commercial Space Station Business and Acquisition of Experimental Module Usage Rights
Jan 13, 2026 14:34 JST
Australia Developers Triumph at the 20th PropertyGuru Asia Property Awards Grand Final
Jan 13, 2026 13:00 JST
Honda to Adopt New "H mark" as Symbol of Honda Automobile Business
Jan 13, 2026 11:26 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Jan 13, 2026 09:50 JST
Mazda Unveils MAZDA CX-6e New Battery EV in World Premiere
Jan 12, 2026 13:10 JST
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 09, 2026 16:03 JST
Honda Announces New Lines of Models that Represent "Honda Sports DNA" at Tokyo Auto Salon 2026
Jan 09, 2026 14:24 JST
Honda Launches Fixed-Battery Electric Two-Wheeled Personal Commuter "Honda UC3" in Thailand and Vietnam
Jan 09, 2026 13:27 JST
Sponsorship Agreement Reached with LCR Honda; Full-Season MotoGP Entry as Pro Honda LCR
Jan 09, 2026 13:05 JST
Mazda Develops New Body Color, "Navy Blue Mica"
Jan 09, 2026 10:23 JST
Fujitsu develops digital learning platform for JAL to support self-directed learning and training management
Jan 09, 2026 10:07 JST
TOYOTA GAZOO Racing Reverting to "GAZOO Racing" to Pass on and Evolve the Making of Ever-better Cars and the Fostering of Talent
Jan 07, 2026 22:04 JST
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Release "The TANAKA 2025" a Perfume that Expresses the Fragrance of Gold (Au)
Jan 07, 2026 22:00 JST
Toyota's European R&D center changes its name and competes in WEC with a new brand
Jan 07, 2026 21:50 JST
More Latest Release >>
Related Release
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
12/3/2025 6:19:00 PM JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
12/3/2025 12:01:00 AM JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
11/28/2025 11:00:00 PM JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
11/26/2025 7:42:00 PM JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
11/17/2025 10:08:00 PM JST
More Press release >>